Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Uterine artery embolization (UAE) is a minimally invasive treatment for women with
symptomatic fibroids. It is similar to hysterectomy in term of satisfaction and symptoms
improvement, with fewer complications and at lower cost. However, the majority of women
undergoing UFE experience important pain after the procedure despite optimal analgesia, with
one third reporting pain equal or worse than labor. Pain is the more common cause of
prolonged hospital stay or readmission. There is need for a simple, efficient way to reduce
post-procedural pain.
For this prospective randomized study, the hypothesis is that an anesthetic drug, lidocaine,
injected in the uterine arteries diminishes pain post-UFE. Patients will be randomized in 3
groups: control, lidocaine injected during embolization, and lidocaine injected after
embolization. Pain will be evaluated using a validated scale at 4h and 24h post-intervention.
Hospital length-of-stay and total narcotic dose administered will be evaluated in the three
groups.
This is the first Canadian study evaluating lidocaine use for pain control in UFE patients.
Results will be transferable to clinical practice, considering the use of lidocaine is simple
and cost is negligible. It could have a great impact on pain management in women undergoing
UFE in all practice settings.